Ticker Details
Prothena Corporation plc Ordinary Shares Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
IPO Date:	December 21, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$485.13M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.90 | 3.12%
Avg Daily Range (30 D):	$0.25 | 2.73%
Avg Daily Range (90 D):	$0.27 | 2.88%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.39M
Avg Daily Volume (90 D):	.4M

Trade Size
Avg Trade Size (Sh.):	76
Avg Trade Size (Sh.) (30 D):	53
Avg Trade Size (Sh.) (90 D):	49

Institutional Trades
Total Institutional Trades:	3,638
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$.73M
Avg Institutional Trade (90 D):	$.9M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.11M
Avg Closing Trade (30 D):	$.72M
Avg Closing Trade (90 D):	$.88M
Avg Closing Volume:	71.63K

News

Jul 7, 2026 @ 10:42 AM Transthyretin Amyloidosis Treatment Market Size to... Source: Sns Insider

Nov 12, 2025 @ 2:24 PM Novo Nordisk's $100 Million Coramitug Shows Promis... Source: Vandana Singh

Aug 29, 2025 @ 2:09 PM FDA Tightens Safety Guidelines For Biogen Leqembi ... Source: Vandana Singh

Feb 17, 2025 @ 11:10 PM Kuehn Law Encourages Investors of Prothena Corpora... Source: N/A

Feb 13, 2025 @ 6:00 PM Alpha-Synuclein Inhibitors Clinical Trial Pipeline... Source: Delveinsight

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.83	$-.36	$.61
Diluted EPS	$-.84	$-.36	$.6
Revenue	$54.53M	$1.01M	$51.08M
Gross Profit
Net Income / Loss	$-43.99M	$-18.58M	$32.72M
Operating Income / Loss	$-55.51M	$-21.1M	$30.04M
Cost of Revenue
Net Cash Flow	$-83.24M	$-19.34M	$M
PE Ratio